Table 1. Correlation between USP33 expression and clinicopathologic characteristics of CRCLM patients.

Variable	n	USP33 expression in primary tumor		P	USP33 expression in CRCLM		P
		Low (N = 86)	High (N = 53)		Low (N = 54)	High (N = 85)
Gender				0.672			0.314
Female	52	31	21		23	29
Male	87	55	32		31	56
Age (year)				0.700			0.796
< 50	42	27	15		17	25
≥ 50	97	59	38		37	60
Primary tumor location				0.664			0.388
Colon	86	52	34		31	55
Rectum	53	34	19		23	30
Primary tumor differentiation				0.771			0.256
Poor	16	11	5		9	7
Moderate	102	63	39		36	66
Well	21	12	9		9	12
Primary tumor staging				0.002*			0.001*
T1–T2	24	8	16		2	22
T3–T4	115	78	37		52	63
Preoperative CEA level				0.754			0.222
< 100 ng/mL	81	51	30		30	56
≥ 100 ng/mL	58	35	23		24	29
Distribution of CRCLM				0.808			0.682
Unilobar	98	60	38		37	61
Bilobar	41	26	15		17	24
No. of CRCLM				0.002*			0.269
< 3	90	47	43		38	52
≥ 3	49	39	10		16	33
Largest diameter of CRCLM				0.647			0.678
< 5 cm	69	44	25		28	41
≥ 5 cm	70	42	28		26	44
Differentiation of CRCLM				0.188			0.713
Poor	6	4	2		3	3
Moderate	120	77	43		47	73
Well	13	5	8		4	9
Resection margin of CRCLM				0.256			0.888
R1	15	7	8		5	10
R0, 1–10 mm	87	58	29		34	53
R0, > 10 mm	37	21	16		15	22
LN metastasis				0.001*			< 0.001*
Negative	36	14	22		5	31
Positive	103	72	31		49	54
Extrahepatic metastasis				0.701			0.087
Negative	120	75	45		50	70
Positive	19	11	8		4	15

Abbreviations: CRCLM: liver metastases of colorectal cancer; CEA: carcinoembryonic antigen; T1: stage I; T2: stage II; T3: stage III; T4: stage IV.